Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27781055 | 0.86 | SMN1; SMN2 (0.57) | ALDH1A1LMNASMN1; SMN2GAAHSD17B10 | |
| SCHEMBL28004 | 0.84 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GAAHSD17B10 | |
| SCHEMBL29453108 | 0.84 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GAAHSD17B10 | |
| SCHEMBL4638087 | 0.84 | ALDH1A1 (0.57) | ALDH1A1LMNASMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL11585746 | 0.82 | ALDH1A1 (0.55) | ALDH1A1LMNASMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL533063 | 0.82 | ALDH1A1 (0.55) | ALDH1A1LMNASMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL4093243 | 0.82 | ALDH1A1 (0.55) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3347957 | 0.82 | CA2 (0.63) | ALDH1A1LMNASMN1; SMN2KMT2APOLB | |
| Hydrochloric Acid SCHEMBL35358 | 0.82 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2GAAHSD17B10 | |
| SCHEMBL1397448 | 0.82 | GAA (0.55) | ALDH1A1LMNASMN1; SMN2GAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021226276-A2 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-3402790-B1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-10-06 | — | — | EP | disclosed |
| US-10759765-B2 | Heterocyclic carboxylic acid amide ligand and applications thereof in copper catalyzed coupling reaction of aryl halogeno substitute | CE PHARM CO., LTD. (CN) | 2020-09-01 | — | — | US | disclosed |
| EP-3312160-B1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10392349-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| WO-2019148851-A1 | FIVE-MEMBERED RING-SUBSTITUTED PYRIDAZINOL COMPOUND AND DERIVATIVES THEREOF, PREPARATION METHOD, HERBICIDAL COMPOSITION, AND APPLICATION | 青岛清原化合物有限公司 | 2019-08-08 | — | — | WO | disclosed |
| WO-2019148850-A1 | PYRIDINE RING-SUBSTITUTED PYRIDAZINOL COMPOUND AND DERIVATIVES THEREOF, PREPARATION METHOD, HERBICIDAL COMPOSITION, AND APPLICATION | 青岛清原化合物有限公司 | 2019-08-08 | — | — | WO | disclosed |
| US-10308605-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| US-20190127337-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE | CE PHARM CO., LTD. (CN) | 2019-05-02 | — | — | US | disclosed |
| US-20190016682-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2019-01-17 | — | — | US | disclosed |
| US-20080262042-A1 | 1-[5-(2-Fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof; acid secretion inhibitor; potassium-competitive acid blocker | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-23 | — | — | US | disclosed |
| WO-2008108380-A2 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-12 | — | — | WO | disclosed |
| US-20080214578-A1 | Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 | ACTURUM REAL ESTATE AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| EP-1869055-A1 | NOVEL 5,7-DISUBSTITUTED Ý1,3¨THIAZOLOÝ4,5-D¨PYRIMIDIN-2(3H)-ONE DERIVATIVES | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| EP-1869056-A1 | NOVEL 5-SUBSTITUTED 7-AMINO-Ý1,3¨THIAZOLOÝ4,5-D¨PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| EP-1803709-A1 | PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006107257-A1 | NOVEL 5,7-DISUBSTITUTED [1,3]THIAZOLO[4,5-D]PYRIMIDIN-2(3H)-ONE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006107258-A1 | NOVEL 5-SUBSTITUTED 7-AMINO-[1,3]THIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262042-A1 | 1-[5-(2-Fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof; acid secretion inhibitor; potassium-competitive acid blocker | REN, HRH2, ATP4A | ALDH1A1 1650/4885LMNA 3758/4885SMN1; SMN2 3936/4885 |
| US-20190016682-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | ALDH1A1 2038/4885LMNA 2166/4885SMN1; SMN2 4568/4885 |
| US-10308605-B2 | Proton pump inhibitors | HRH2, HRH4, HRH1 | ALDH1A1 2593/4885LMNA 3457/4885SMN1; SMN2 4075/4885 |
| US-10392349-B2 | Azepane derivatives and methods of treating hepatitis B infections | HAVCR2, HDGF, AZI2 | ALDH1A1 2038/4885LMNA 2166/4885SMN1; SMN2 4568/4885 |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | PTGER1, PTGER3, NR3C1 | ALDH1A1 1764/4885LMNA 4165/4885SMN1; SMN2 2491/4885 |
| US-20190127337-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE | AOC1, AOC2, AOC3 | ALDH1A1 79/4885LMNA 4664/4885SMN1; SMN2 4066/4885 |
| US-20080214578-A1 | Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 | CX3CR1, CCR2, CXCR3 | ALDH1A1 1833/4885LMNA 4330/4885SMN1; SMN2 1516/4885 |
| US-10759765-B2 | Heterocyclic carboxylic acid amide ligand and applications thereof in copper catalyzed coupling reaction of aryl halogeno substitute | AOC1, AOC2, AOC3 | ALDH1A1 79/4885LMNA 4664/4885SMN1; SMN2 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.